Climb Bio, Inc. CLYM
12.25 USD +0.51 (+4.34%)
At closeNov 11, 2026, 5:41 PM EST
12.30 +0.05 +0.41%
After hours · Nov 11, 5:41 PM ET
11.49 Day range 12.44
1.64 52-week range 18.33
- YTD
- +206.25%
- 1 year
- +544.74%
News
benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.
benzinga.com Climb Bio Q3 EPS $(0.18) Beats $(0.20) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 5.26 percent increase over losses of $(0.19) per…
globenewswire.com Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in…- benzinga.com Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
globenewswire.com Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,…
benzinga.com Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…- benzinga.com Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval~70% reduction in Gd-IgA1 at 12 weeks~33-day half-lifeNAVIGATE-2 Phase 2 trial enrolling, with initial data…
benzinga.com Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28 Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
benzinga.com Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026 Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
benzinga.com Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25 Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.
benzinga.com Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
- benzinga.com B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30 B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
benzinga.com BTIG Maintains Buy on Climb Bio, Raises Price Target to $32 BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
benzinga.com Baird Maintains Outperform on Climb Bio, Raises Price Target to $25 Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
benzinga.com Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $24.
- benzinga.com Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25 Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $17 to $25.
- benzinga.com Climb Bio Q2 EPS $(0.18) Beats $(0.21) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.21) by 14.29 percent. This is a 38.46 percent decrease over losses of $(0.13)…
benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $17 to $20.- benzinga.com HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy and maintains $20 price target.
- benzinga.com Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies Up to $100,000,000Common StockWe have entered into an Open Market Sale AgreementSM, or the Sales Agreement, with Jefferies LLC, or Jefferies, dated as of June 12, 2026, relating to the sale of shares…
benzinga.com Why Is Climb Bio Stock Gaining Friday? Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletion and strong platelet responses.- benzinga.com BTIG Maintains Buy on Climb Bio, Raises Price Target to $20 BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $19 to $20.
- benzinga.com Climb Bio Announces Initial Data From Its Ongoing Phase 1b Portion Of Its Phase 1b/2a Study Evaluating Budoprutug In Adults With Primary Immune Thrombocytopenia Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b…
benzinga.com Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive trial data. Other big gainers include ENHA, JLHL, ABAT, BTGO, GLXY, CLYM, SOC, SRAD, AIAI, ALOY, and…- benzinga.com Guggenheim Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $35 Guggenheim analyst Yatin Suneja initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $35.
- benzinga.com Climb Bio Plans To Share Initial PK/PD Data And Updated Safety Data From Ongoing Phase 1 Studies Of CLYM116 In Healthy Volunteers, At Next Installment Of Its R&D Spotlight Series The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD) data, as well as updated safety data from the ongoing Phase 1 studies of CLYM116 in healthy…
- benzinga.com Climb Bio To Present Translational Pharmacometric Modeling And Initial Phase 1 Safety Data For CLYM116, Anti-APRIL Monoclonal Antibody, At ERA Congress 2026 Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summerInitiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in…
benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $20 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $15 to $20.- benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $17 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $15 to $17.
- benzinga.com Climb Bio Q1 EPS $(0.20) Beats $(0.29) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 35.48 percent increase over losses of $(0.31)…
- benzinga.com BTIG Maintains Buy on Climb Bio, Raises Price Target to $19 BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $8 to $19.
- benzinga.com Chardan Capital Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $22 Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $22.
- benzinga.com Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $18 Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $10 to $18.
- benzinga.com Mizuho Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $18 Mizuho analyst Joseph Catanzaro initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $18.
benzinga.com This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Wall Street analysts have changed their outlook on top names, with new coverage and price targets. See the latest analyst ratings and opinions.- benzinga.com Truist Securities Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $17 Truist Securities analyst Danielle Brill initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $17.
- benzinga.com HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $15 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $11 to $15.
- benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $14 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $12 to $14.
- benzinga.com Baird Maintains Outperform on Climb Bio, Raises Price Target to $12 Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $9 to $12.
- benzinga.com Wedbush Initiates Coverage On Climb Bio with Outperform Rating, Announces Price Target of $12 Wedbush analyst Laura Chico initiates coverage on Climb Bio (NASDAQ:CLYM) with a Outperform rating and announces Price Target of $12.
- benzinga.com Climb Bio Q4 EPS $(0.26) Misses $(0.18) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.18) by 46.07 percent. This is a 100 percent decrease over losses of $(0.13)…
benzinga.com This Taiwan Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com Piper Sandler Initiates Coverage On Climb Bio with Overweight Rating, Announces Price Target of $23 Piper Sandler analyst Yasmeen Rahimi initiates coverage on Climb Bio (NASDAQ:CLYM) with a Overweight rating and announces Price Target of $23.
- benzinga.com Climb Bio Announces First Patients Dosed In Budoprutug PrisMN Phase 2 Trial In pMN; Anticipates Data-Rich 2026, With Initial Readouts From All Ongoing Budoprutug And CLYM116 Studies First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved…
- benzinga.com Alumis And Acelyrin Issue Breach Notice To Climb Bio Over Unpaid $3M Milestone Due January 1, 2026 On January 2, 2026, Alumis Inc. (the "Company") and its wholly-owned subsidiary Acelyrin, Inc. ("Acelyrin") issued a Notice of Material Breach and Notification of Claim for Indemnification to Climb…
- benzinga.com Climb Bio Files Lawsuit Against Alumis And Acelyrin Seeking Declaratory Judgment Over Budoprutug Milestone Payment Dispute On December 31, 2025, Climb Bio, Inc. (the "Company") filed a complaint (the "Complaint") in Delaware Superior Court against Alumis Inc. ("Alumis") and its wholly owned subsidiary, Acelyrin, Inc.…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com GE Vernova To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday